Gene polymorphisms and antigen levels of matrix metalloproteinase-1 in type 2 diabetes mellitus coexisting with coronary heart disease

Kardiologia Polska

Volumn 66, Issue 10, 2008, Pages 1042-1048

  Drzewoski, Józef ^a   Śliwińska, Agnieszka ^a   Przybyłowska, Karolina ^b   Śliwiński, Tomasz ^b   Kasznicki, Jacek ^a   Zurawska Klis, Monika ^a   Kosmalski, Marcin ^a   Majsterek, Ireneusz ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

Coronary heart disease; Genetic polymorphism; Metalloproteinases; Type 2 diabetes mellitus

Indexed keywords

INTERSTITIAL COLLAGENASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DNA POLYMORPHISM; ENZYME BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENOTYPE; GLUCOSE METABOLISM; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 55049109212     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. El-Atat F, McFarlane SI, Sowers JR. Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr Hypertens Rep 2004; 6: 215-23.
2. Meerarani P, Badimon JJ, Zias E, et al. Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications. Curr Mol Med 2006; 6: 501-14.
3. Rouis M. Matrix metalloproteinases: a potential therapeutic target in atherosclerosis. Curr Drug Targets Cardiovasc Haematol. Disord 2005; 5: 541-8.
4. Uemura S, Matsushita H, Li W, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001; 88: 1291-8.
5. Death AK, Fisher EJ, McGrath KC, et al. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003; 168: 263-9.
6. Li N, Karin M. Is NF-?B the sensor of oxidative stress? FASEB J 1999; 13: 1137-43.
7. Balbin M, Fueyo A, Knauper V, et al. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem 2001; 276: 10253-62.
8. Rutter JL, Mitchell TI, Buttice G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998; 58: 5321-5.
9. Jurajda M, Muzik J, Izakovicova Holla L, et al. A newly identified single nucleotide polymorphism in the promoter of the matrix metalloproteinase-1 gene. Mol Cell Probes 2002; 16: 63-6.
10. Dunleavey L, Beyzade S, Ye S. Rapid genotype analysis of the matrix mettaloproteinase-1 gene 1G/2G polymorphism that is associated with risk of cancer. Matrix Biol 2000; 19: 175-7.
11. Ruderman N, Haudenschild C. Diabetes as an atherogenic factor. Prog Cardiovasc Dis 1984; 26: 373-412.
12. Uemura S, Matsushita H, Li W, et al. Diabetes mellitus enhances vascular matix metalloproteinase activity: role of oxidative stress. Circ Res 2001; 88: 1291-8.
13. McLennan SV, Fisher E, Martell SY, et al. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int Suppl 2000; 77: S81-7.
14. Lobmann R, Pap T, Ambrosch A, et al. Differential effects of PDGF-BB on matrix metalloproteases and cytokine release in fibroblasts of Type 2 diabetic patients and normal controls in vitro. J Diabetes Complications 2006; 20: 105-12.
15. Kumar MS, Vamsi G, Sripriya R, et al. Expression of matrix metalloproteinases (MMP-8 and -9) in chronic periodontitis patients with and without diabetes mellitus. J Peridontol 2006; 11: 1806-11.
16. Noda K, Ishida S, Inoue M, et al. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2003; 44: 2163-70.
17. Abdella NA. Controversies in management of diabetes in patients with coronary heart disease. Med Princ Pract 2002; 11: (Suppl 2) 69-74.
18. Polyakova V, Hein S, Kostin S, et al. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004; 19: 1609-18.
19. Tyagi SC, Kumar SG, Haas SJ, et al. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol 1996; 28: 1415-28.
20. Parsons SL, Watson SA, Brown PD, et al. Matrix metalloproteinases. J Clin Invest 1997; 84: 160-6.
21. Wilmer W, Cosio F. DNA binding of activator protein-1 is increased in human mesangial cells cultured in high glucose concentrations. Kidney Int 1998; 53: 1172-81.
22. Du X, Stocklauser-Farber K, Rosen P. Generation of reactive oxygen intermediates, activation of NF-kappaB, and induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase. Free Radic Biol Med 1999; 27: 752-63.
23. Okuda Y, Adrogue HJ, Nakajima T, et al. Increased production of PDGF by angiotensin and high glucose in human vascular endothelium. Life Sci 1996; 59: 1455-61.
24. Pascal M, Knott R, Forrester J. Glucose mediated regulation of transforming growth factor beta in human retinal endothelial cells. Biochem Soc Trans 1996; 24: 228S.
25. Jormsjö S, Ye S, Moritz J, et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000; 86: 998-1003.
26. Maeda S, Haneda M, Guo B, et al. Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. Kidney Int 2001; 60: 1428-34.
27. Horne BD, Camp NJ, Carlquist JF, et al. Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am Heart J 2007; 154: 751-8.
28. Liu PY, Chen JH, Li YH, et al. Synergistic effect of stromelysin-1 (matrix metallo-proteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost 2003; 90: 132-9.
29. Liu PY, Li YH, Chan SH, et al. Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome. Am J Cardiol 2006; 15: 98: 1012-7.
30. Ghilardi G, Biondi ML, DeMonti M, et al. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis Stroke 2002; 33: 2408-12.
31. Su L, Zhou W, Park S, et al. Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 567-70.
32. Su L, Zhou W, Asomaning K, et al. Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis 2006; 5: 1024-29.
33. Ye S, Gale CR, Christopher NM. Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur Heart J 2003: 24: 1668-71.
34. Zinzindohoue F, Lecomte T, Ferraz J-M, et al. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphism in colorectal cancer. Clin Cancer Res 2005; 11: 594-9.
35. Hirata H, Okayama N, Naito K, et al. Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal carcinoma. Carcinogenesis 2004; 25: 2379-84.